| Metric | This Period | Prior Year Period | YoY |
|---|---|---|---|
| Revenue / Net Sales | ¥101.9B | ¥81.4B | +25.2% |
| Operating Income / Operating Profit | ¥-0.7B | ¥-1.2B | +37.2% |
| Ordinary Income | ¥0.6B | ¥0.1B | -99.3% |
| Net Income / Net Profit | ¥-0.6B | ¥-0.8B | +17.3% |
| ROE | -0.5% | -0.5% | - |
For the quarter ended March 2026 (Q1), Revenue was ¥101.9B (YoY +¥20.5B, +25.2%), Operating Income was ¥-0.7B (YoY +¥0.5B, +37.2%), Ordinary Income was ¥0.6B (YoY +¥0.5B, +472.0%), and Net Income attributable to owners of the parent was ¥-0.6B (YoY +¥0.1B, +17.3%). The core Human Resources Platform business drove high growth with Revenue of ¥70.3B (+27.6%), and the Medical Platform business expanded to ¥28.9B (+26.3%). The operating loss narrowed to ¥-0.7B (improved from ¥-1.2B a year earlier), but the ordinary profit was materially supported by non-operating income of ¥2.1B (mainly gain on sale of affiliates’ shares ¥1.6B and gain on business transfer ¥0.5B—one-off factors). A tax burden of ¥0.8B exceeded pre-tax profit of ¥0.1B, resulting in continued net loss.
[Revenue] Revenue was ¥101.9B (YoY +25.2%), sustaining high growth. By segment, the Human Resources Platform business accounted for ¥70.3B (+27.6%, 69.0% of total) and generated Operating Income of ¥17.1B (margin 24.3%), leading growth as the primary profit engine. The Medical Platform business expanded to ¥28.9B (+26.3%, 28.4% share) but recorded an Operating Loss of ¥-1.7B (deteriorating from Operating Profit ¥2.0B year-ago), leaving monetization challenges. New Development Services contracted to ¥2.7B (▲22.2%) with an Operating Loss of ¥-1.6B (prior ¥-1.5B), continuing in a loss phase. Gross profit was ¥56.0B, with a gross margin of 55.0% (down ▲4.2pt from 59.2% a year earlier), suggesting changes in sales mix and a higher proportion of lower-margin projects.
[Profit and Loss] SG&A was ¥56.7B (prior ¥49.4B, +14.8%), though the SG&A ratio improved to 55.7% (down ▲5.0pt from 60.7%) reflecting economies of scale from revenue growth. Combined segment Operating Income was ¥13.8B (prior ¥13.8B, flat), but corporate overhead and adjustments of ¥-14.4B (prior ¥-15.0B) pressured consolidated profit, producing an Operating Loss of ¥-0.7B (prior ¥-1.2B; loss narrowed 37.2%). Non-operating income of ¥2.1B (prior ¥2.4B) included gain on sale of affiliates’ shares ¥1.6B and gain on business transfer ¥0.5B—largely one-off. Non-operating expenses were ¥0.8B (prior ¥1.2B), mainly interest expense ¥0.5B. Ordinary Income was ¥0.6B (prior ¥0.1B), but recording of Extraordinary Loss ¥0.5B compressed Pre-Tax Profit to ¥0.1B, and income taxes ¥0.8B (effective tax rate approx. 615%) produced a Net Loss of ¥-0.6B. In conclusion, while revenue increased, operating loss narrowed, and ordinary profitability improved, dependency on non-operating gains and high tax burden resulted in a final net loss.
The Human Resources Platform business delivered Revenue ¥70.3B (+27.6%) and Operating Income ¥17.1B (+28.4%) with margin 24.3% (up +0.1pt from 24.2%), maintaining high profitability and balancing growth and returns. The Medical Platform business grew Revenue to ¥28.9B (+26.3%) but swung to an Operating Loss of ¥-1.7B (from Operating Profit ¥2.0B prior), a significant deterioration; margin was ▲5.8% (down ▲14.4pt from +8.6%). In the prior year Q1, goodwill of ¥5,187M was recorded related to the acquisition of AxisRoute Holdings subsidiary, implying amortization and integration costs may have impacted results. New Development Services Revenue shrank to ¥2.7B (▲22.2%) with Operating Loss ¥-1.6B (prior ¥-1.5B, loss widened +5.8%), margin ▲61.3% (from ▲45.0%, down ▲16.3pt), indicating continued investment phase. Corporate overhead and adjustments of ¥-14.4B (prior ¥-15.0B) offset combined segment profits of ¥13.8B and continue to pressure consolidated operating profit.
[Profitability] Operating margin was ▲0.7% (improved +0.8pt from ▲1.5%), Net margin was ▲0.6% (improved +0.3pt from ▲0.9%)—losses narrowed but remain negative. Gross margin was 55.0% (down ▲4.2pt from 59.2%), reflecting sales mix changes; SG&A ratio improved to 55.7% (down ▲5.0pt from 60.7%), indicating cost efficiency from scale. ROE was ▲0.5% (prior ▲0.5%, flat) driven by persistently low net margin. [Cash Quality] DSO was 126 days (worse by +17 days from 109), and CCC was 122 days (worse by +27 days from 95), indicating deterioration in cash collection efficiency and emerging credit/receivables management issues as the company grows. [Investment Efficiency] Total asset turnover improved to 0.93x (from 0.79x) aided by revenue expansion, but with Total Assets ¥436.8B (prior ¥412.5B, +5.9%), profit generation remains low. [Financial Health] Equity Ratio was 29.9% (down ▲6.0pt from 35.9%), D/E ratio worsened to 2.35x (from 1.79x), increasing leverage. Interest coverage was ▲1.34x (Operating Income ¥-0.7B / Interest Expense ¥0.5B), showing lack of resilience to interest burden under operating loss. Long-term borrowings ¥152.4B (34.9% of total assets) are pressuring finances. Cash and equivalents ¥109.9B (prior ¥85.8B, +28.2%) secure liquidity; Current Ratio improved to 136.4% (from 128.7%). Intangible assets ¥231.3B (53.0% of total assets) and goodwill ¥129.2B (98.9% of equity) indicate heavy balance sheet dependence on M&A-derived intangibles, increasing vulnerability to impairment risk.
Although the cash flow statement is not disclosed, balance sheet trends indicate cash movements: cash and equivalents increased to ¥109.9B (prior ¥85.8B, +¥24.1B), strengthening liquidity. Conversely, trade receivables rose to ¥35.1B (prior ¥30.4B, +¥4.7B) with DSO at 126 days, extending collection terms. Contract liabilities (advance receipt nature) slightly decreased to ¥22.3B (prior ¥23.1B, ▲¥0.8B). Long-term borrowings increased significantly to ¥152.4B (prior ¥123.0B, +¥29.4B), and total interest-bearing debt rose to ¥157.2B (prior ¥126.8B, +¥30.4B). Given the operating loss, operating cash flow generation is likely limited; the cash increase appears primarily driven by higher borrowings. With interest expense ¥0.5B continuing, urgent need exists to strengthen self-generated cash via operating profitability and working capital efficiency.
Ordinary Income of ¥0.6B in the period relied on non-operating income of ¥2.1B (2.1% of Revenue), consisting mainly of gain on sale of affiliates’ shares ¥1.6B and gain on business transfer ¥0.5B—largely one-off. While ordinary profit was achieved despite Operating Loss ¥-0.7B, core operating earning power remains negative; most of the ¥1.3B gap between Ordinary Income and Operating Income is attributable to one-time gains. Recording of Extraordinary Loss ¥0.5B compressed Pre-Tax Profit to ¥0.1B, and income taxes ¥0.8B (effective tax rate approx. 615%) produced a Net Loss of ¥-0.6B. The abnormal high tax rate likely reflects constraints on recognition of deferred tax assets, non-deductible items (e.g., goodwill amortization), and the reversal of prior-year tax refunds. The discrepancy between Ordinary Income and Net Income (¥-0.6B − ¥-0.6B = ¥-1.2B) is driven by special items and tax burden; restoring sustainable operating profitability and normalizing tax effects are focal points going forward for earnings quality.
Against the full-year guidance (Revenue ¥464.0B, Operating Income ¥29.5B, Ordinary Income ¥32.5B, Net Income ¥18.0B), Q1 progress rates are: Revenue 22.0% (standard progress 25%: ▲3.0pt), Operating Income ▲2.3% (miss due to operating loss), Ordinary Income 1.9%, Net Income ▲3.4% (miss due to net loss). Revenue growth +25.2% trails the full-year forecast pace of +26.1%. The start with an operating loss is underwhelming. Achieving full-year targets assumes: operating profitability in H2 and recovery in gross margins; restraint of corporate overhead; accelerated growth in the core Human Resources Platform business; and monetization progress in the Medical Platform business. There is no revision to performance or dividend forecasts this quarter; the company maintains its plan, but improvement pace from Q2 onward will be watched closely.
Dividend forecast remains ¥0.00 for the full year; no dividend policy change. With Net Loss ¥-0.6B, Operating Loss ¥-0.7B, and Interest Coverage ▲1.34x, the earnings base is fragile and distributable capacity is not evident. Retained earnings are ¥75.1B (prior ¥75.8B, slight decline), providing some internal buffer, but given high leverage (D/E 2.35x), ongoing interest burden, and impairment risks on goodwill and intangibles, prioritizing growth investment and strengthening financial health is reasonable. Future shareholder returns would require stable operating profitability, reduced interest burden, and improved Equity Ratio.
Leverage and interest burden risk: With D/E ratio 2.35x (worsened from 1.79x) and interest-bearing debt ¥157.2B (36.0% of total assets), the company is highly leveraged; Interest Coverage at ▲1.34x under operating loss shows little resilience to interest burden. Ongoing quarterly interest expense of ¥0.5B and potential interest rate increases, changes in borrowing terms, or covenant breaches could constrain finances. Management of repayment schedules and refinancing costs for long-term borrowings ¥152.4B is important.
Dependence on intangibles and impairment risk: Intangible assets ¥231.3B (53.0% of total assets) and goodwill ¥129.2B (99% of equity) show heavy balance sheet reliance on M&A-derived intangibles. A deterioration in business conditions or profitability could trigger impairment losses that materially erode equity. The Medical Platform’s Operating Loss ¥-1.7B (deteriorated from +¥2.0B) and continuing losses in New Development Services may signal impairment triggers; recoverability of goodwill and impairment test outcomes are key to financial stability.
Working capital inefficiency and liquidity risk: DSO 126 days (worsened +17 days) and CCC 122 days (worsened +27 days) indicate extended receivable collection and rising working capital demands with growth. With Trade Receivables ¥35.1B (prior ¥30.4B, +15.5%) rising and limited operating cash generation, additional external financing may be required, risking cash flow rigidity. Tightening credit management, optimizing collection terms, and leveraging contract liabilities for advance payments are urgent priorities.
Profitability & Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | -0.7% | 6.2% (4.2%–17.2%) | -6.9pt |
| Net Margin | -0.6% | 2.8% (0.6%–11.9%) | -3.4pt |
Profitability is well below industry median; improving operating performance is urgently needed.
Growth & Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth (YoY) | 25.2% | 20.9% (12.5%–25.8%) | +4.3pt |
Revenue growth exceeds industry median and ranks high within the sector, but low margins constrain the quality of growth.
※ Source: Company aggregation
Timing and sustainability of operating profitability: This quarter narrowed the operating loss to ¥-0.7B (from ¥-1.2B), but substantial improvement in H2 is required to reach the full-year Operating Income target of ¥29.5B. While the core Human Resources Platform maintains high margin (24.3%), the Medical Platform’s Operating Loss ¥-1.7B (worsened from +¥2.0B) and corporate overhead ¥-14.4B weigh heavily. Reversal of the gross margin decline (55.0%, down ▲4.2pt) and further SG&A ratio improvement are prerequisites for stable operating profitability; subsequent quarterly trends should be monitored to assess the timing and permanence of profit turnaround.
Rebuilding financial leverage and cash generation: High leverage (D/E 2.35x) and Interest Coverage ▲1.34x indicate fragility to interest costs. Although long-term borrowings increased to ¥152.4B to reinforce funding, operating losses limit autonomous cash generation. DSO 126 days and CCC 122 days signal deteriorating working capital efficiency. Stabilizing operating cash flow, accelerating receivables collection, and gradually reducing interest-bearing debt are conditions for restoring financial health. High dependence on intangibles (goodwill/equity ~99%) lowers tolerance to impairments; monitoring business-level earnings and impairment indicators will be critical for medium-term financial stability.
This report was automatically generated by AI analyzing XBRL financial statement data. It does not constitute a recommendation to invest in any specific security. Industry benchmarks are reference information aggregated by the Company based on public financial statements. Investment decisions are your responsibility; consult a professional advisor as appropriate.